PRME
Prime Medicine, Inc.
A biotechnology company developing "Prime Editing," a gene-editing technology that acts like a molecular word processor, able to search for and rewrite faulty DNA without cutting both strands like earlier CRISPR "scissors." Founded in 2019, Prime Medicine aims to turn this science into one-time treatments for serious inherited diseases, and its lead therapy targets chronic granulomatous disease, a rare immune disorder. The company takes its name from the Prime Editing technology it was built around.
CUSIP: 74168J101HealthcareUS2 holders
Recent Activity
2026Q2
1 buy1 sell
-59.6K shares(-1.2%)
-59.6K shares(-1.2%)
+2.10M shares(+33.6%)
ARK InvestADD
+2.10M shares(+33.6%)
2026Q1
1 buy1 sell
-29.8K shares(-0.6%)
-29.8K shares(-0.6%)
+878.3K shares(+16.4%)
ARK InvestADD
+878.3K shares(+16.4%)
Loading more activity...